Prøve GULL - Gratis
NIO Super Specialty Hospital expands services
Chronicle Pharmabiz
|July 24, 2025
NATIONAL Institute of Ophthalmology (NIO), one of the leading super specialty eye care hospitals in India, recently expanded its services and facilities in Pune. It has launched 2 new clinics and has integrated surgical simulation equipment in order to reach more patients and upgrade its services for them.
-
Speaking on the expansion, Dr. Aditya Kelkar, director, NIO Super Specialty Hospital said, “In the past 3 decades, our organization has been at the forefront of the revolution being brought within the ophthalmology sector. We have always strived to integrate new technology and accelerate the progress being made in the research and development within the sector. Therefore, this expansion of our services and facilities is in line with our goal to provide our patients with access to the best in eye healthcare solutions. We are confident that we will be able to help several communities across th
Denne historien er fra July 24, 2025-utgaven av Chronicle Pharmabiz.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Chronicle Pharmabiz
Chronicle Pharmabiz
US FDA fortifies alliance with Telangana DCA
A high-level delegation from the US FDA concluded a significant meeting with the DCA in Telangana, two days ago, at the DCA office in Hyderabad.
2 mins
December 11, 2025
Chronicle Pharmabiz
India exploring possibilities to expand WHO standards for Indian medicines
INDIA is looking at possibilities to expand the World Health Organisation (WHO) global benchmarking standards for medicines, in order to unify and strengthen the drug regulatory mechanism for safety, quality and efficacy of medicines sold in the country.
1 min
December 11, 2025
Chronicle Pharmabiz
Eli Lilly gets US FDA approval for Jaypirca
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.
1 mins
December 11, 2025
Chronicle Pharmabiz
Haryana DCA focuses on quality overhaul
THE Haryana drug control administration (DCA) is undertaking a major organizational overhaul focused on quality system upgrades and regulatory capacity building, particularly in response to the revised Schedule M norms.
2 mins
December 11, 2025
Chronicle Pharmabiz
DoC seeks inputs on trade issues faced with Japan
THE Department of Commerce (DoC), under the Union Commerce Ministry, has sought inputs from the industry on specific issues being faced in pharma trade with Japan.
1 min
December 11, 2025
Chronicle Pharmabiz
AIOCD asks traders to strictly comply with ban on 35 FDCs
THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).
3 mins
December 11, 2025
Chronicle Pharmabiz
US FDA approves Bristol Myers Squibb's Breyanzi
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
2 mins
December 11, 2025
Chronicle Pharmabiz
CN Water presents AQU@Sense MB
CN Water is now combining core water-system expertise with digital assurance has launched AQU@Sense which delivers microbial test results in under 30 minutes, replacing traditional 5 to 7 days culture based methods.
1 min
December 11, 2025
Chronicle Pharmabiz
Pharma logistics sees policy push as key catalyst for growth
INDIAN pharma's logistics sector is getting major boost from emerging policy support.
2 mins
December 11, 2025
Chronicle Pharmabiz
Lack of financial aid, expertise mar MSME prospects to meet revised Sch M deadline
INDUSTRY experts have raised alarm that lack of financial assistance and guidance on technical expertise have marred pharma MSMEs’ prospects to comply with revised Schedule M guidelines of December 31, 2025.
2 mins
December 11, 2025
Listen
Translate
Change font size